References
- van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–442.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
- Sangar VK, Ragavan N, Matanhelia SS, et al. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005;95:59–63.
- James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am. 2013;40:261–269.
- Hermann GG, Mogensen K, Lindvold LR, et al. Office-based transurethral devascularisation of low grade non-invasive urothelial cancer using diode laser. A feasibility study. Lasers Surg Med. 2015;47:620–625.
- Hermann GG, Mogensen K, Carlsson S, et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011;108:E297–E303.
- Lindvold LR, Hermann GG. An optical method for reducing green fluorescence from urine during fluorescence-guided cystoscopy. Methods Appl Fluoresc. 2016;4:0450002.
- Mogensen K, Christensen KB, Vrang ML, et al. Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol. 2016;50:170–174.
- Sobin LH, Wittekind C, editors. TNM classification of malignant tumors. 6th ed. Hoboken (NJ): John Wiley & Sons; 2002.
- World Health Organization (WHO). WHO classification of tumours: pathology & genetics. Tumours of the urinary system and male genital organs. Lyon (France): IARC Press; 2004.
- Busse R, Geissler A, Quentin W, et al. editors. Diagnosis-related groups in Europe. European Observatory on Health Systems and Policies Series. New York (NY): McGraw Hill/Open University Press; 2011.
- Sundhedsdata Styrelsen. Interaktiv DRG.2017. Available from: http://drgservice.ssi.dk/grouper/Modules/Home/
- DBCR 2010 årsrapport. Dansk BlaereCancer Register & Forskningscenter for Forebyggelse og Sundhed. [Internet] 2012. Available from: http://ducg.dk/dablaca-blaerecancer/aarsrapporter/
- Wong KA, Zisengwe G, Athanasiou T, et al. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int. 2013;112:561–567.
- Kramer MW, Wolters M, Cash H, et al. Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014. World J Urol. 2015;33:571–579.
- Syed HA, Talbot N, Abbas A, et al. Flexible cystoscopy and holmium: yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia. J Endourol. 2013;27:886–891.
- Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103:577–644.
- Johnson DE. Use of the holmium:YAG (Ho:YAG) laser for treatment of superficial bladder carcinoma. Lasers Surg Med. 1994;14:213–218.
- Xishuang S, Deyong Y, Xiangyu C, et al. Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol. 2010;24:69–73.
- Zhong C, Guo S, Tang Y, et al. Clinical observation on 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experience. World J Urol. 2010;28:157–161.
- Hermann GG, Mogensen K, Toft BG, et al. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 2012;46:31–36.
- Kamphuis GM, de Bruin DM, Brandt MJ, et al. Comparing image perception of bladder tumors in four different Storz professional image enhancement system modalities using the iSPIES app. J Endourol. 2016;30:602–608.
- Kamphuis GM, de Bruin DM, Fallert J, et al. Storz Professional Image Enhancement System: a new technique to improve endoscopic bladder imaging. J Cancer Sci Ther. 2016;8:71–77.